SQLite Web: event

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.nasdaq.com/articles/viking-therapeutics-gears-q1-earnings-heres-what-expect","as_of":"2026-04-21T13:49:56.265209+00:00","canonical_url":"https://www.nasdaq.com/articles/viking-therapeutics-gears-q1-earnings-heres-what-expect","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/viking-therapeutics-gears-q1-earnings-heres-what-expect","article_chars":4063,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_9dca01d29d81cd1f","canonical_host":"nasdaq.com","canonical_is_aggregator":false,"canonical_url":"https://www.nasdaq.com/articles/viking-therapeutics-gears-q1-earnings-heres-what-expect","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-21T23:44:51.169833+00:00","extraction_method":"trafilatura","fetched_description":"VKTX heads into Q1 earnings results with a focus on pipeline updates, as it expects no revenues and continued losses amid key obesity drug developments.","fetched_title":"Viking Therapeutics Gears Up for Q1 Earnings: Here's What to Expect | Nasdaq","final_url":"https://www.nasdaq.com/articles/viking-therapeutics-gears-q1-earnings-heres-what-expect","html_truncated":false,"paywall_likely":false,"publisher_domain":"nasdaq.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/viking-therapeutics-gears-q1-earnings-heres-what-expect","source_event_id":"evt_794dcdd82fd8","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"e60fa36f19c80919","kind":"new_listings","published_at":"2026-04-21T12:35:00+00:00","publisher_domain":"nasdaq.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["first-quarter 2026","Q1 2026","third quarter of 2026","end of first-quarter 2026","next year"],"entities":[{"asset_class":"equity","name":"Viking Therapeutics, Inc.","relevance":"high","symbol":"VKTX","type":"company"},{"asset_class":"biotech_pipeline","name":"VK2735","relevance":"high","symbol":"","type":"pipeline_candidate"},{"asset_class":"biotech_pipeline","name":"VK2809","relevance":"medium","symbol":"","type":"pipeline_candidate"},{"asset_class":"biotech_pipeline","name":"VK0214","relevance":"medium","symbol":"","type":"pipeline_candidate"},{"asset_class":"clinical_study","name":"VANQUISH-1","relevance":"medium","symbol":"","type":"clinical_study"},{"asset_class":"clinical_study","name":"VANQUISH-2","relevance":"medium","symbol":"","type":"clinical_study"},{"asset_class":"biotech_pipeline","name":"DACRA (dual amylin and calcitonin receptor agonist)","relevance":"medium","symbol":"","type":"pipeline_candidate"},{"asset_class":"regulator","name":"FDA","relevance":"medium","symbol":"","type":"regulator"}],"event_type":"earnings","information_gaps":["The article does not provide the exact date of the Q1 2026 earnings release.","No specific revenue figures are given (only that none are expected).","The article does not specify the exact timing or expected results for VK2809 and VK0214 beyond general \u201cprogress\u201d and collaboration prospects.","The article does not state whether the Earnings ESP/Zacks Rank information is current as of a specific date/time beyond \u201cat present.\u201d"],"key_facts":["The article expects Viking Therapeutics to report first-quarter 2026 earnings with investor focus on pipeline updates.","In the last reported quarter, the company\u2019s earnings missed expectations by more than 55%.","Because the company lacks a marketed drug, no revenues are expected to be recorded.","The Zacks Consensus Estimate for earnings is a loss of 95 cents per share.","The pipeline updates expected to be discussed include three candidates: VK2735 (obesity), VK2809 (NASH), and VK0214 (X-ALD).","The company is conducting two late-stage studies (VANQUISH-1 and VANQUISH-2) on the subcutaneous formulation of VK2735.","VANQUISH-1 evaluates VK2735 in obese adults with at least one weight-related co-morbid condition and without type II diabetes (T2D).","VANQUISH-2 evaluates VK2735 in obese or overweight adults with T2D.","Data from VANQUISH-1 and VANQUISH-2 is not expected before next year.","The article expects updates on the study design for the late-stage program on the oral version of VK2735, previously planned to start in Q3 2026.","The article expects an update on the internally developed DACRA candidate.","The article states Viking Therapeutics previously announced plans to file an IND application with the FDA for the DACRA candidate before the end of Q1 2026 to start clinical studies in the obesity indication.","The article expects updates on NASH and X-ALD programs, including progress on collaboration prospects.","Over the past four quarters, earnings missed estimates in each quarter, with a negative average surprise of 30.80%.","Year-to-date, VKTX shares have gained 1% versus the industry\u2019s 3.5% growth.","The article states VKTX has an Earnings ESP of 0.00% and a Zacks Rank #3 (Hold) at present."],"numeric_claims":[{"label":"last quarter earnings miss","value":"more than 55%"},{"label":"Zacks Consensus Estimate (loss per share)","value":"$0.95 loss per share"},{"label":"negative average earnings surprise (past four quarters)","value":"30.80%"},{"label":"year-to-date share gain (VKTX)","value":"1%"},{"label":"year-to-date industry growth","value":"3.5%"}],"primary_claim":"Viking Therapeutics expects no revenues in its first-quarter 2026 earnings because it has no marketed drug, and investors will focus on pipeline updates including VK2735, VK2809, and VK0214.","relevance_score":0.62,"sentiment":"mixed","source_quality":"high","summary":"Viking Therapeutics (VKTX) is expected to report first-quarter 2026 earnings focused on pipeline updates, with no marketed-drug revenues and continued losses. The article highlights late-stage obesity studies for VK2735 and upcoming regulatory/clinical milestones for other pipeline candidates.","topics":["first-quarter 2026 earnings","pipeline updates","obesity drug development","clinical trial progress","no marketed-drug revenues","expected losses per share","earnings surprise history","Zacks Consensus Estimate","Earnings ESP and Zacks Rank"]},"source":"Nasdaq Stocks","source_domain":"nasdaq.com","summary":"VKTX heads into Q1 earnings results with a focus on pipeline updates, as it expects no revenues and continued losses amid key obesity drug developments.","tickers":[],"title":"Viking Therapeutics Gears Up for Q1 Earnings: Here's What to Expect","url":"https://www.nasdaq.com/articles/viking-therapeutics-gears-q1-earnings-heres-what-expect"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

event_store.db — signals

Update row sig_1f15a7c100fe in signals